Posted in HEDIS Measures, Training, Updates

New and Retired Medicaid HEDIS measures (NCQA 2020/2021)

Source: Empire BCBS NY

New HEDIS Medicaid Measures:

  1. Kidney Health Evaluation for Patients With Diabetes (KED) — The percentage of members 18 to 85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a uACR identified by both a quantitative urine albumin test and a urine creatinine test with service days four or less days apart during the measurement year

2. Cardiac Rehabilitation (CRE) — The percentage of members 18 years and older who attended cardiac rehabilitation following a qualifying cardiac event, including myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation, or heart valve repair/replacement; four rates are reported:

  • Initiation — The percentage of members who attended two or more sessions of cardiac rehabilitation within 30 days after a qualifying event
  • Engagement 1 — The percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event
  • Engagement 2 — The percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event
  • Achievement — The percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event

Retired Medicaid measures:

  • Comprehensive Diabetes Care (CDC) retired sub-measures —
    • Medical Attention for Nephropathy (retired for Commercial and Medicaid)
    • HbA1c control (< 7.0%) for a selected population
  • Adult BMI Assessment (ABA)
  • Medication Management for People With Asthma (MMA)
  • Children’s and Adolescents’ Access to Primary Care Practitioners (CAP)
Advertisement
Posted in Uncategorized

Announcement: Pharmacy Benefit Coverage Update – Effective May 1, 2020 & July 1, 2020 – UnitedHealthcare Commercial Plans

The original pharmacy formulary for UHC Commercial Pharmacy Benefits Plans was scheduled to take place on May 1,2020.

However, due to the current circumstances UHC revised their Pharmacy Benefits update and pushed it to become effective on July 1,2020.

According to UHC statement the change was done: “…to allow additional time for you and your patient to discuss alternative therapies when appropriate…”

This change applies to the following medications:

1. Diabetes-Insulin: Basaglar KwikPen, Levemir, Levemir FlexTouch and Tr

a. Lantus, Lantus SoloSTAR, Toujeo Max SoloSTAR and Toujeo SoloSTAR are currently excluded but will be added to the coverage on July 1,2020

2. Diabetes- Non-Insulin: Janumet, Janumet XR and Januvia

3. Neuromuscular Disorders: Firdapse

Step Therapy for Zomig will be required effective July 1,2020

Asthma- Arnuity Ellipta, Flovent Disus, Flovent HFA and Pulmicort Flexhaler will be covered at this time until further notice. However, these medications are still on tier 3 for UHC commercial Plans pharmacy benefit plans.

Since there are multiple prescription drug lists exist, please feel free to refer to patient-specific information received through e-prescribing or UHC PreCheck MyScript tool on Link.